Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies (Q33825182)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

Europe PubMed Central

Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

Green LL

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

publication date

1 December 1999

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Journal of Immunological Methods

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

231

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1-2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

11-23

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Anaphylactic shock after retreatment with OKT3 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Engineering Antibodies for Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Preparation of clone libraries in yeast artificial-chromosome vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Clinical pharmacology and therapeutic potential of monoclonal antibody treatment in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

A directory of human germ-line V kappa segments reveals a strong bias in their usage

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Germ-line transmission and expression of a human-derived yeast artificial chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Use of rituximab, the new FDA-approved antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Antigen-specific human antibodies from mice comprising four distinct genetic modifications

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Reshaping human antibodies for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Ten years of Orthoclone OKT3 (muromonab-CD3): a review

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Humanized monoclonal antibody for prevention of respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Inactivation of the mouse HPRT locus by a 203-bp retroposon insertion and a 55-kb gene-targeted deletion: establishment of new HPRT-deficient mouse embryonic stem cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: gene-segment use in mu and gamma transcripts

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Preferential utilization of specific immunoglobulin heavy chain diversity and joining segments in adult human peripheral blood B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Human antibodies by design

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

The use of antibodies against the IL-2 receptor in transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

The pharmacology of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Man-made antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Immunologic and pharmacologic concepts of monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

Organization of the human immunoglobulin heavy-chain locus

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900137-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0022-1759(99)00137-4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33825182&oldid=1947734414"